Mind Medicine unveils changes at the top as it advances its psychedelic medicine strategy

Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) (FRA:MMQ) has unveiled some leadership changes as the company advances its strategy of combining clinical development programs with digital technologies. 

J.R. Rahn will become the sole chief executive of the psychedelic medicine biotech, while Stephen Hurst will retire from his co-CEO and executive chairman positions, but will remain a director. 

READ: MindMed announces start of first-ever clinical trial evaluating the combination of MDMA and LSD in humans

Stanley Glick has retired as a director but will continue to act as a scientific advisor, the firm added. His director role will be filled after completing an extensive search and interview process.

Director Perry Dellelce becomes chair of the board of directors.

Thus, the team now includes Dr. Miri Wernli Halperin as president and head of clinical and Carol Nast as chief operating officer, as well as Robert Barrow who was recently hired as the group’s chief development officer.

“Steve and Dr. Glick played instrumental early roles in establishing a world-class scientific and drug development team,” noted J.R. Rahn in a statement.

“I am grateful for their contributions to get us to today and look forward to continuing to have trusted scientific guidance moving forward. As we increase our headcount and grow our MindMed ‘Ark’ of technologists, drug developers, scientific researchers, regulatory experts, psychiatrists and drug manufacturing specialists, the entire psychedelic medicine space is edging closer to getting these potential medicines into the hands of patients.

“In doing so, we must also turn our efforts and open our unified strategy to technology, distribution platforms and other growth opportunities to remain a leader in this space. Our streamlined leadership team and MindMed 2.0 strategy will continue to help define MindMed as a leader in the psychedelics space and as a specialist in digital medicine.”

Mindmed said it was “actively growing” its digital medicine division for psychedelic medicines through the hiring of new technologists and undertaking potential technology platform acquisitions.

Contact the author at [email protected]

Story by ProactiveInvestors